$ELAN
Elanco Animal Health Inc

2023 Q2 Form 10-Q Financial Statement

#000173910423000009 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $1.057B $1.257B
YoY Change -10.2% 2.61%
Cost Of Revenue $434.0M $494.0M
YoY Change -10.33% -2.95%
Gross Profit $623.0M $763.0M
YoY Change -10.1% 6.56%
Gross Profit Margin 58.94% 60.7%
Selling, General & Admin $353.0M $327.0M
YoY Change 2.92% 2.19%
% of Gross Profit 56.66% 42.86%
Research & Development $81.00M $81.00M
YoY Change -1.22% 0.0%
% of Gross Profit 13.0% 10.62%
Depreciation & Amortization $177.0M $173.0M
YoY Change 3.51% -1.7%
% of Gross Profit 28.41% 22.67%
Operating Expenses $434.0M $408.0M
YoY Change 2.12% 1.75%
Operating Profit $189.0M $355.0M
YoY Change -29.48% 12.7%
Interest Expense $74.00M $64.00M
YoY Change 10.45% 23.08%
% of Operating Profit 39.15% 18.03%
Other Income/Expense, Net -$23.00M -$9.000M
YoY Change 0.0%
Pretax Income -$79.00M $108.0M
YoY Change 338.89% 52.11%
Income Tax $18.00M $5.000M
% Of Pretax Income 4.63%
Net Earnings -$97.00M $103.0M
YoY Change 340.91% 114.58%
Net Earnings / Revenue -9.18% 8.19%
Basic Earnings Per Share -$0.20 $0.21
Diluted Earnings Per Share -$0.20 $0.21
COMMON SHARES
Basic Shares Outstanding 492.6M shares 491.5M shares
Diluted Shares Outstanding 492.6M shares 492.8M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $367.0M $318.0M
YoY Change -27.61% -7.02%
Cash & Equivalents $367.0M $318.0M
Short-Term Investments
Other Short-Term Assets $370.0M $370.0M
YoY Change 9.47% 17.46%
Inventory $1.690B $1.596B
Prepaid Expenses
Receivables $1.000B $1.051B
Other Receivables $225.0M $213.0M
Total Short-Term Assets $3.652B $3.548B
YoY Change 10.43% 11.08%
LONG-TERM ASSETS
Property, Plant & Equipment $1.007B $1.000B
YoY Change 4.79% 1.32%
Goodwill $6.040B $6.061B
YoY Change 2.41% -0.9%
Intangibles $4.678B $4.791B
YoY Change -7.53% -11.2%
Long-Term Investments $27.00M $27.00M
YoY Change -12.9% 17.39%
Other Assets $419.0M $369.0M
YoY Change 11.44% -33.99%
Total Long-Term Assets $12.14B $12.22B
YoY Change -1.22% -6.4%
TOTAL ASSETS
Total Short-Term Assets $3.652B $3.548B
Total Long-Term Assets $12.14B $12.22B
Total Assets $15.80B $15.77B
YoY Change 1.25% -2.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $354.0M $381.0M
YoY Change -8.29% -5.22%
Accrued Expenses $110.0M
YoY Change -0.9%
Deferred Revenue $332.0M $329.0M
YoY Change 16.9% 11.53%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $39.00M $381.0M
YoY Change -30.36% 524.59%
Total Short-Term Liabilities $1.284B $1.578B
YoY Change -4.04% 20.73%
LONG-TERM LIABILITIES
Long-Term Debt $6.023B $5.639B
YoY Change 0.27% -7.15%
Other Long-Term Liabilities $411.0M $245.0M
YoY Change 69.83% 1.24%
Total Long-Term Liabilities $6.434B $5.884B
YoY Change 2.96% -6.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.284B $1.578B
Total Long-Term Liabilities $6.434B $5.884B
Total Liabilities $8.376B $8.289B
YoY Change -1.0% -4.05%
SHAREHOLDERS EQUITY
Retained Earnings -$1.051B -$954.0M
YoY Change 13.87% 5.88%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.420B $7.480B
YoY Change
Total Liabilities & Shareholders Equity $15.80B $15.77B
YoY Change 1.25% -2.97%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$97.00M $103.0M
YoY Change 340.91% 114.58%
Depreciation, Depletion And Amortization $177.0M $173.0M
YoY Change 3.51% -1.7%
Cash From Operating Activities $61.00M -$145.0M
YoY Change -80.45% 133.87%
INVESTING ACTIVITIES
Capital Expenditures $42.00M $20.00M
YoY Change -227.27% 5.26%
Acquisitions $16.00M
YoY Change
Other Investing Activities -$1.000M $1.000M
YoY Change -75.0% -66.67%
Cash From Investing Activities -$43.00M -$55.00M
YoY Change 16.22% 89.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.00M $174.0M
YoY Change -140.63% -187.0%
NET CHANGE
Cash From Operating Activities 61.00M -$145.0M
Cash From Investing Activities -43.00M -$55.00M
Cash From Financing Activities 39.00M $174.0M
Net Change In Cash 57.00M -$27.00M
YoY Change -68.16% -90.88%
FREE CASH FLOW
Cash From Operating Activities $61.00M -$145.0M
Capital Expenditures $42.00M $20.00M
Free Cash Flow $19.00M -$165.0M
YoY Change -94.49% 103.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001739104
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38661
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Elanco Animal Health Inc
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
IN
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5497352
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2500 INNOVATION WAY
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
GREENFIELD
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IN
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
46140
CY2023Q1 dei City Area Code
CityAreaCode
877
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
352-6261
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, no par value
CY2023Q1 dei Trading Symbol
TradingSymbol
ELAN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
492550481 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1257000000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1226000000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
494000000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
509000000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81000000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81000000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
327000000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
323000000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
134000000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
137000000 usd
CY2023Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
40000000 usd
CY2022Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
40000000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
64000000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
52000000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
1149000000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1151000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
108000000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
75000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1538000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
103000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
51000000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
491100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
488000000.0 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
492800000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
492200000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
103000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
51000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-48000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
109000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
130000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-85000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
82000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
185000000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74000000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
318000000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
345000000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
15000000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
13000000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1051000000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
797000000 usd
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
213000000 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
205000000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1596000000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
370000000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
394000000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
3548000000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3279000000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
6061000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
5993000000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4791000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4842000000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
369000000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
378000000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
744000000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
723000000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1000000000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
999000000 usd
CY2023Q1 us-gaap Assets
Assets
15769000000 usd
CY2022Q4 us-gaap Assets
Assets
15491000000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
381000000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
390000000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
110000000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
146000000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
329000000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
324000000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
381000000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
388000000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
454000000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1578000000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1702000000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5639000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5448000000 usd
CY2023Q1 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
164000000 usd
CY2022Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
161000000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
663000000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
662000000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
245000000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
229000000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
8289000000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8202000000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
492418216 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
492418216 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
474237738 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
474237738 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8744000000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8738000000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-954000000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1057000000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-310000000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-392000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7480000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7289000000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15769000000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15491000000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7508000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
51000000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14000000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
11000000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7585000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7289000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
103000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
82000000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7480000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
103000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
51000000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
173000000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2000000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7000000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12000000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14000000 usd
CY2023Q1 elan Asset Impairment Charges Including Inventory Write Down
AssetImpairmentChargesIncludingInventoryWriteDown
0 usd
CY2022Q1 elan Asset Impairment Charges Including Inventory Write Down
AssetImpairmentChargesIncludingInventoryWriteDown
22000000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-1000000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-1000000 usd
CY2023Q1 elan Business Combination Inventories Step Up Fair Value Adjustment
BusinessCombinationInventoriesStepUpFairValueAdjustment
1000000 usd
CY2022Q1 elan Business Combination Inventories Step Up Fair Value Adjustment
BusinessCombinationInventoriesStepUpFairValueAdjustment
0 usd
CY2023Q1 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
439000000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
332000000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2000000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
13000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-145000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62000000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000000 usd
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16000000 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14000000 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
CY2023Q1 us-gaap Payments For Software
PaymentsForSoftware
4000000 usd
CY2022Q1 us-gaap Payments For Software
PaymentsForSoftware
7000000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
1000000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000000 usd
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
200000000 usd
CY2022Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
63000000 usd
CY2023Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
19000000 usd
CY2022Q1 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
89000000 usd
CY2023Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
CY2022Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
163000000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7000000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-11000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174000000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-200000000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-296000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
345000000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
638000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
318000000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
342000000 usd
CY2023Q1 elan Number Of Brands In Entitys Portfolio
NumberOfBrandsInEntitysPortfolio
200 brand
CY2023Q1 us-gaap Number Of Countries In Which Entity Operates
NumberOfCountriesInWhichEntityOperates
90 country
CY2023Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies set forth in Note 4 to the consolidated financial statements in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> appropriately represent, in all material respects, the current status of our accounting policies.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Revision of Previously Issued Consolidated Financial Statements</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified and corrected relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. In conjunction with making these corrections, we made other adjustments to the prior years to revise uncorrected errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. Further information is included in Note 2 and Note 21 to the consolidated financial statements in our </span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1739104/000173910423000004/elan-20221231.htm#iabf0ca0eda714084ad9b96b0b7cac563_70" style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Form 10-K</a></span><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
324000000 usd
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
319000000 usd
CY2023Q1 elan Contract With Customer Liability Revenue Recognized Including Current Year Additions
ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions
209000000 usd
CY2022Q1 elan Contract With Customer Liability Revenue Recognized Including Current Year Additions
ContractWithCustomerLiabilityRevenueRecognizedIncludingCurrentYearAdditions
219000000 usd
CY2023Q1 elan Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
204000000 usd
CY2022Q1 elan Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
241000000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
329000000 usd
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
297000000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1257000000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1226000000 usd
CY2022Q1 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
55000000 usd
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
0 usd
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
-7000000 usd
CY2023Q1 us-gaap Business Exit Costs1
BusinessExitCosts1
0 usd
CY2022Q1 us-gaap Business Exit Costs1
BusinessExitCosts1
1000000 usd
CY2023Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
40000000 usd
CY2022Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
24000000 usd
CY2023Q1 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
0 usd
CY2022Q1 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
22000000 usd
CY2023Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
40000000 usd
CY2022Q1 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
40000000 usd
CY2023Q1 elan Restructuring Expected Payment Term
RestructuringExpectedPaymentTerm
P12M
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
749000000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
725000000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000000 usd
CY2023Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
299000000 usd
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
266000000 usd
CY2023Q1 us-gaap Inventory Gross
InventoryGross
1653000000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
1596000000 usd
CY2023Q1 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
57000000 usd
CY2022Q4 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
58000000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1596000000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1538000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5448000000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
60000000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
64000000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
6020000000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
5836000000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
381000000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
388000000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5639000000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
27000000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
27000000 usd
CY2023Q1 us-gaap Interest Rate Cash Flow Hedge Gain Loss Reclassified To Earnings Net
InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet
27000000 usd
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-4000000 usd
CY2022Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-3000000 usd
CY2023Q1 us-gaap Interest Rate Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months Net
InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
87000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.044
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.316
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.044
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000000 usd
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.316
CY2020Q4 elan Loss Contingency Percent Of Te Us Issued Involved In Lawsuit
LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit
0.0500
CY2023Q1 elan Lessee Operating Lease Lease Not Yet Commenced Liability To Be Paid
LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaid
378000000 usd
CY2023Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P25Y
CY2023Q1 elan Tax Incremental Financing Estimated Total Incentive To Be Funded
TaxIncrementalFinancingEstimatedTotalIncentiveToBeFunded
64000000 usd
CY2021Q4 elan Tax Incremental Financing Commitment Amount
TaxIncrementalFinancingCommitmentAmount
64000000 usd
CY2022Q4 elan Tax Incremental Financing Expect To Refund Within Next Three Months
TaxIncrementalFinancingExpectToRefundWithinNextThreeMonths
15000000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1257000000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1226000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
103000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
51000000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
491100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
488000000.0 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1700000 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4200000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
492800000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
492200000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1400000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares

Files In Submission

Name View Source Status
elan-20230331_cal.xml Edgar Link unprocessable
elan-20230331_pre.xml Edgar Link unprocessable
0001739104-23-000009-index-headers.html Edgar Link pending
0001739104-23-000009-index.html Edgar Link pending
0001739104-23-000009.txt Edgar Link pending
0001739104-23-000009-xbrl.zip Edgar Link pending
elan-20230331.htm Edgar Link pending
elan-20230331.xsd Edgar Link pending
elan-20230331_g1.jpg Edgar Link pending
ex311elanco-20230331xceoce.htm Edgar Link pending
ex312elanco-20230331xcfoce.htm Edgar Link pending
ex32elanco-20230331xsectio.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
elan-20230331_def.xml Edgar Link unprocessable
elan-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elan-20230331_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending